OnDosis and Adare Pharma Formed Partnership
The companies have joined forces to develop an extended-release ADHD treatment for the U.S. market.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you believe partnerships between drug and device companies help improve treatment options for patients?
OnDosis and Adare Pharma Solutions have announced a strategic collaboration to develop an extended-release oral pellet product for ADHD treatment. The partnership leverages OnDosis' precision dosing platform for the U.S. market.
Why it matters
The collaboration aims to facilitate pivotal bioequivalence studies and a 505(b)(2) regulatory submission for OnDosis' ADHD medication, Imfocy. This agreement combines specialized manufacturing services with innovative precision dosing hardware.
This partnership targets the development of an extended-release oral pellet product containing mixed amphetamine salts. The scope covers end-to-end manufacturing services for the US market.
The players
OnDosis
A Swedish company that specializes in developing drug-device combination products for precision dosing.
Adare Pharma Solutions
A contract development and manufacturing organization that provides pharmaceutical development and production services.
The details
Adare Pharma Solutions will serve as the contract development and manufacturing organization (CDMO) to support OnDosis in refining its drug-device combination. The project integrates the Dosage Manager device platform to enable individualized dosing for patients.
Timeline
October 1, 2026: OnDosis and Adare announced the strategic collaboration.
Market Landscape
This alliance reflects a growing trend of specialized hardware companies seeking established manufacturing partners to navigate complex regulatory hurdles. The collaboration follows the regulatory requirements set by the FDA 505(b)(2) pathway to streamline approval of the ADHD drug.
Patients may eventually see new ADHD treatment options that utilize precision dosing technology if the development program succeeds. This partnership currently serves as a corporate-level development milestone rather than an immediate change to medication availability.
The takeaway
Precision dosing platforms represent a shift toward highly personalized medication delivery systems. These technologies aim to improve patient compliance and therapeutic efficacy by allowing for precise control of drug dosage.
Further reading
Learn more about the latest developments in the Healthcare sector.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe partnerships between drug and device companies help improve treatment options for patients?
